NICE Rules Out Sanofi’s Jevtana On Grounds Of Cost Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has turned down Sanofi’s Jevtana for prostate cancer, raising fears in England of a new post-code lottery for cancer drugs and highlighting the different between Germany and England’s health technology assessments.